A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
Clinical trial NCT07618546 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07618546
- Sponsor
- Henan Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-25
- Primary completion
- 2027-03-31
- Enrollment
- 208
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.